PHARMA &
BIOPHARMA
IN FRANCE

KEY INFO IN
10
POINTS
1. **THE WORLD’S 5TH LARGEST PHARMA MARKET**

   France is the fifth largest market in the world for human medicines, and the second largest in Europe. In 2015, revenues from pharmaceuticals exceeded €53 billion, nearly half of which were generated by exports. (LEEM Pharmaceutical Industry Association, 2016)

2. **SANOFI: AN INNOVATIVE LEADER**

   Sanofi is the third largest healthcare firm in the world, ranking 19th among multinationals for research investment (The 2015 EU Industrial R&D Investment Scoreboard). One of its products, Dengvaxia, is the world’s first approved dengue vaccine, with 100 million doses produced every year in France.

3. **FRANCE’S PROWESS IN VACCINES**

   France is a leading player in the global vaccines market, with world-renowned institutions such as the Institut Pasteur International Network (RIIP), totaling 23,000 personnel overseeing 768 projects at 33 establishments in 26 countries on every continent. The RIIP plays a major role in particular against emerging infections wherever they occur across the globe.

4. **€25 BILLION IN PHARMACEUTICAL EXPORTS**

   French pharmaceutical exports rose 1.5% from 2014 to €25.4 billion in 2015. The EU was the most frequent destination (€14 billion, 57%), ahead of America (15.3%), Africa (12.3%), Asia (11%), and the Middle East (4.1%). Germany (€2.7 billion), Belgium (€2.6 billion) and the United States (€2.5 billion) were the three leading countries. (LEEM Pharmaceutical Industry Association, 2016)
France’s global market share in pharmaceutical exports was 6.1% in 2015 (UN Comtrade), while in 2016 France’s trade balance in the sector generated a surplus of €3.9 billion. Pharmaceutical products accounted for 6.6% of French exports in 2016. (French Customs Authorities)

Pharmaceutical specialties whose efficacy and safe use can be assumed, but which have not yet obtained market approval or been tested in clinical trials, may nevertheless be granted temporary authorization for use (Autorisation temporaire d’utilisation – ATU) in exceptional circumstances as a last resort.

Nearly 99,000 people are employed directly by pharmaceutical companies in France, including 42,000 in manufacturing operations. Fifty percent of the 20,000 people working in R&D hold a research position. (LEEM Pharmaceutical Industry Association, 2016)
INVESTING IN RESEARCH

The pharmaceutical industry has one of the highest business enterprise R&D budgets of any sector in France, accounting for 9.8% of pharmaceutical company revenues. [LEEM Pharmaceutical Industry Association, 2016]

ASTRAZENECA INVESTING €135 BILLION IN FRANCE

In 1990, Anglo-Swedish company AstraZeneca first set up operations in Dunkirk (Hauts de France region), where it currently employs 450 people to produce two asthma medicines. In 2016, the firm invested €135 million at the site, which exports 90% of its output throughout the world.

FRANCE RANKED #1 FOR VETERINARY PRODUCTS

France is the leading country in Europe for research and production of veterinary products and reagents, with revenues in the French market amounting to €833 million, and export sales adding a further €1.2 billion (including €700 million within the EU). French companies Merial, Virbac, Ceva and Vetoquinol are ranked among the 10 leading laboratories in the world. [SIMV Veterinary Medicine Industry Association, 2015]
For further information, please visit:
www.businessfrance.fr
FRANCE:

#1 IN THE WORLD FOR LIFE EXPECTANCY AT 65 YEARS

(OECD, 2015)
52

JOB-CREATING FOREIGN INVESTMENT PROJECTS IN THE FRENCH HEALTHCARE SECTOR IN 2016

(BUSINESS FRANCE)
France: the world’s 5th largest market for human medicines

(LEEM Pharmaceutical Industry Association, 2016)
FRANCE: INVENTOR OF THE WORLD’S 1st APPROVED DENGUE VACCINE